Prosensa And Partners Awarded Second European Consortium FP7 Research Grant

Leiden, The Netherlands and Newcastle, UK, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, and Newcastle University, UK, have announced the award of a second Framework Programme 7 (FP7) research grant from the European Commission. This new FP7 research grant totals approximately EUR 6 million to support the development of imaging biomarkers for Duchenne muscular dystrophy (DMD).

The project - "Developing imaging technologies for therapeutic interventions in rare diseases" - will be known as "BIOIMAGE-NMD" and is expected to run three and a half years.

"The overarching objective of the BIOIMAGE-NMD project is to deliver combined structural and molecular imaging biomarkers with proven utility for the detection of therapeutic effects in patients with rare neuromuscular diseases (NMD) including DMD," Professor Andrew Blamire, Professor of Magnetic Resonance Physics at the Newcastle Magnetic Resonance Centre at Newcastle University, said. "We hope to be able to show that using simultaneous MRI and magnetic resonance spectroscopic imaging (MRSI) is an effective tool to monitor biomarkers that indicate therapeutic efficacy of drugs tested in clinical trials in neuromuscular diseases, including DMD, to ultimately speed development and bring much needed therapies to patients in a more efficient manner."

The pan-European BIOIMAGE-NMD consortium includes leading expert centers in DMD already working together in another recently awarded FP7 project called SCOPE-DMD ( ) as well as additional partners with strong expertise and experience in bio-imaging. The SCOPE-DMD project, which was initiated earlier this year, was also awarded EUR 6 million as announced previously. This FP7 project aims to evaluate Prosensa's exon 45 skipping drug candidate, PRO045, in an innovatively designed clinical proof-of-concept study in boys with DMD.

The academic partners in the BIOIMAGE-NMD project are Newcastle University  as the coordinating partner, and University College London (UCL) in the United Kingdom; the Institute of Myology in France; the Leiden University Medical Centre in The Netherlands; Universita Cattolica del Sacro Cuore (UCSC) in Italy; and the Katholieke Universiteit Leuven (KULeuven) in Belgium. These academic centers are working alongside a number of industrial partners including Prosensa, SCITO, based in France, and Consultants for Research in Imaging and Spectroscopy (CRIS).

If you liked this article you might like

Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year

Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains

Prosensa Holding (RNA) Upgraded From Sell to Hold

The Nominees for Best Biotechnology Co. CEO of 2014 Are...

Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta